Inogen, Inc. (INGN)

NASDAQ: INGN · Real-Time Price · USD
6.30
-0.08 (-1.25%)
May 18, 2026, 4:00 PM EDT - Market closed
Market Cap170.57M -10.7%
Revenue (ttm)351.50M +3.4%
Net Income-24.90M
EPS-0.92
Shares Out 27.07M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume326,079
Open6.36
Previous Close6.38
Day's Range6.28 - 6.54
52-Week Range5.34 - 9.13
Beta1.65
AnalystsStrong Buy
Price Target12.67 (+101.11%)
Earnings DateMay 7, 2026

About INGN

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airw... [Read more]

Sector Healthcare
IPO Date Feb 14, 2014
Employees 753
Stock Exchange NASDAQ
Ticker Symbol INGN
Full Company Profile

Financial Performance

In 2025, Inogen's revenue was $348.67 million, an increase of 3.86% compared to the previous year's $335.71 million. Losses were -$22.75 million, -36.62% less than in 2024.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for INGN stock is "Strong Buy." The 12-month stock price target is $12.67, which is an increase of 101.11% from the latest price.

Price Target
$12.67
(101.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Inogen reports Q1 EPS (30c), one estimate (21c)

Reports Q1 revenue $85.1M, two estimates $82.4M. “Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities…

11 days ago - TheFly

Inogen Earnings Call Transcript: Q1 2026

Q1 2026 revenue grew 3.4% year-over-year to $85.1 million, led by 18% international growth, while U.S. sales declined. New product launches and international expansion are expected to drive full-year growth, with profitability improvements anticipated in Q2 and Q3.

11 days ago - Transcripts

Inogen Slides: Q1 2026

Inogen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.

11 days ago - Filings

Inogen Earnings release: Q1 2026

Inogen released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.

11 days ago - Filings

Inogen Quarterly report: Q1 2026

Inogen has published its Q1 2026 quarterly earnings report on May 7, 2026.

11 days ago - Filings

Inogen Announces First Quarter 2026 Financial Results

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2026 Financial Results.

11 days ago - Business Wire

Inogen Proxy statement: Proxy filing

Inogen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.

20 days ago - Filings

Inogen to Report First Quarter 2026 Financial Results on May 7, 2026

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report First Quarter 2026 Financial Results on May 7, 2026.

25 days ago - Business Wire

Inogen Proxy statement: Proxy filing

Inogen filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.

4 weeks ago - Filings

Inogen Transcript: 25th Annual Needham Virtual Healthcare Conference

Leadership expansion and strategic hires support transformation into a broader respiratory care platform. New product launches, including Voxi 5, Simeox, and Aurora masks, are expected to drive growth and margin improvement, while B2B channel gains offset DTC headwinds. Share repurchases and disciplined spending reinforce a focus on shareholder value.

4 weeks ago - Transcripts

Inogen initiated with a Buy at Freedom Broker

Freedom Broker initiated coverage of Inogen (INGN) with a Buy rating and $12 price target The firm says Inogen is a respiratory-focused company and home medical equipment provider transitioning from…

6 weeks ago - TheFly

Inogen Announces the Appointment of Vafa Jamali to Board of Directors

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Vafa Jamali to Board of Directors.

6 weeks ago - Business Wire

Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference.

6 weeks ago - Business Wire

Inogen backs FY26 revenue view $366M-$373M, two estimates $368.9M

16:05 EDT Inogen (INGN) backs FY26 revenue view $366M-$373M, two estimates $368.9M

7 weeks ago - TheFly

Inogen names Jason Richardson CFO, Dominic Hulton CMO

Inogen (INGN) announced the following leadership appointments designed to accelerate the company’s next phase of growth. Jason Richardson has been appointed Chief Financial Officer, effective April 6,...

7 weeks ago - TheFly

Inogen backs Q1 revenue view of in line with 1Q25

16:04 EDT Inogen (INGN) backs Q1 revenue view of in line with 1Q25

7 weeks ago - TheFly

Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

7 weeks ago - Business Wire

Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth.

7 weeks ago - Business Wire

Inogen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Management outlined a successful transformation to a diversified portfolio, expanding TAM and returning to profitable growth. New products and international expansion are expected to drive 6% revenue growth in 2026, with a focus on margin improvement and high single-digit growth over the next 3–5 years.

2 months ago - Transcripts

Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum.

2 months ago - Business Wire

Inogen Earnings Call Transcript: Q4 2025

Delivered 4% revenue growth in 2025, returned to positive adjusted EBITDA, and launched new products expanding the addressable market to $3.4B. Guidance for 2026 targets 6% revenue growth and continued profitability, supported by a $30M share repurchase program.

2 months ago - Transcripts

Inogen Annual report: Q4 2025

Inogen has published its Q4 2025 annual report on February 24, 2026.

2 months ago - Filings

Inogen Earnings release: Q4 2025

Inogen released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.

2 months ago - Filings

Inogen Slides: Q4 2025

Inogen has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.

2 months ago - Filings

Inogen Annual report: Q4 2025

Inogen has published its Q4 2025 annual report on February 24, 2026.

2 months ago - Filings